Glaukos (NYSE:GKOS) PT Raised to $100.00

Glaukos (NYSE:GKOS - Free Report) had its price objective lifted by Mizuho from $85.00 to $100.00 in a report released on Thursday morning, Benzinga reports. They currently have a neutral rating on the medical instruments supplier's stock.

A number of other brokerages have also weighed in on GKOS. Truist Financial reaffirmed a buy rating and issued a $110.00 price target on shares of Glaukos in a research note on Monday. StockNews.com downgraded Glaukos from a hold rating to a sell rating in a research report on Tuesday, February 27th. Piper Sandler lifted their price target on Glaukos from $90.00 to $105.00 and gave the company an overweight rating in a research report on Friday, December 22nd. Stifel Nicolaus reissued a buy rating and issued a $110.00 price objective on shares of Glaukos in a research note on Wednesday, April 3rd. Finally, Needham & Company LLC raised their target price on Glaukos from $105.00 to $108.00 and gave the company a buy rating in a research note on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $99.80.

Glaukos Stock Performance

Glaukos stock traded down $0.45 during mid-day trading on Thursday, hitting $99.26. 374,204 shares of the company's stock traded hands, compared to its average volume of 697,211. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. Glaukos has a one year low of $45.38 and a one year high of $102.33. The firm has a 50 day moving average price of $91.53 and a 200 day moving average price of $79.84. The company has a market cap of $4.91 billion, a PE ratio of -35.71 and a beta of 1.08.

Glaukos (NYSE:GKOS - Get Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.07). The business had revenue of $82.40 million for the quarter, compared to analyst estimates of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. Glaukos's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period last year, the business posted ($0.53) earnings per share. On average, equities analysts forecast that Glaukos will post -2.18 EPS for the current year.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 4,890 shares of the company's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $89.17, for a total transaction of $436,041.30. Following the completion of the sale, the chief operating officer now directly owns 119,802 shares of the company's stock, valued at $10,682,744.34. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Alex R. Thurman sold 583 shares of the firm's stock in a transaction on Thursday, January 18th. The stock was sold at an average price of $90.54, for a total value of $52,784.82. Following the completion of the sale, the chief financial officer now owns 54,618 shares of the company's stock, valued at $4,945,113.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Joseph E. Gilliam sold 4,890 shares of the firm's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $89.17, for a total value of $436,041.30. Following the sale, the chief operating officer now owns 119,802 shares of the company's stock, valued at $10,682,744.34. The disclosure for this sale can be found here. Insiders sold a total of 248,464 shares of company stock valued at $23,405,250 over the last three months. Insiders own 7.80% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Natixis Advisors L.P. boosted its position in Glaukos by 4.0% during the third quarter. Natixis Advisors L.P. now owns 33,979 shares of the medical instruments supplier's stock valued at $2,557,000 after purchasing an additional 1,298 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Glaukos by 5.6% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 386,790 shares of the medical instruments supplier's stock valued at $29,106,000 after buying an additional 20,415 shares in the last quarter. Wealthcare Advisory Partners LLC bought a new stake in shares of Glaukos in the 3rd quarter valued at approximately $204,000. Lisanti Capital Growth LLC acquired a new position in Glaukos in the third quarter worth approximately $6,367,000. Finally, Strs Ohio lifted its stake in Glaukos by 45.8% in the third quarter. Strs Ohio now owns 3,500 shares of the medical instruments supplier's stock valued at $263,000 after acquiring an additional 1,100 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.